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Abstract
A cytocompatible visible light-mediated interfacial thiol-norbornene photopolymerization scheme 
was developed for creating hydrogel conformal coating on pancreatic islets. The step-growth thiol-
norbornene reaction affords high consistency and tunability in gel coating thickness. Furthermore, 
isolated islets coated with thiol-norbornene gel maintained their viability and function in vitro.
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by auto-reactive T-cells 
that destroy insulin-producing pancreatic β-cells in the islets of Langerhans.1 The 
destruction of β-cells leads to inadequate insulin secretion and hyperglycemia. Current 
standard of therapy to restore glucose homeostasis is through multiple daily insulin 
injections or implantation of insulin delivery devices.2 However, tight glycemic control 
through insulin administration requires frequent monitoring of blood glucose levels. In 
addition, patients experience various degrees of discomfort from exogenous insulin delivery. 
While whole pancreas or islet transplantation can provide T1DM patients with insulin-
independence, these approaches are reserved for diabetic patients with hypoglycemia 
unawareness due to a significant shortage of donor organs.3-5 The outcome of islet 
transplantation, however, is heavily influenced by blood mediated inflammatory response 
(IBMIR), which can destroy more than half of the transplanted islets shortly after surgery.6-8 
Furthermore, patients receiving donor islets are required to undergo lifelong 
immunosuppressant therapy. To improve the lifespan of transplanted islets, scientists and 
engineers have been developing encapsulation technologies to separate allogenic or even 
xenogenic islets from host tissues.9-18 A successful permselective immune isolation barrier 
should be able to prevent infiltration of host immune cells while permitting facile exchange 
of nutrients and metabolites, including oxygen, glucose, and insulin.2
A variety of encapsulation technologies have been developed for forming islet surface 
coating, including macromolecular self-assembly,13, 15, 19 cell surface engineering,13 and 
covalent cross-linking of hydrogels.2, 20 For example, islets can be encapsulated in 
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polyplexes formed by layer-by-layer (LbL) self-assembly of ionic macromolecules (e.g., 
polyanionic alginate with divalent barium or calcium cations).21-23 Biotin-streptavidin 
affinity binding and hydrogen bonding between polar macromers have also been explored 
for forming multi-layer polymer coating for islet encapsulation.24-26 The long-term stability 
of these physically assembled coatings is easily affected by tissue conditions at the 
transplantation site, such as pH and ionic strength.27, 28 Alternatively, islets can be 
encapsulated through cell surface engineering. In one example, islets were functionalized 
with hetero-bifunctional maleimide-poly(ethylene glycol)-lipid (maleimide-PEG-lipid), 
which was conjugated with thiol-containing molecules via thiol-maleimide Michael-type 
addition.29-31 Conformal coating of islets can also be formed by visible light-mediated 
chain-growth polymerization of acrylate-based macromers 9, 26, 32-35 In addition to the 
macromer PEG-diacrylate (PEGDA), co-initiator triethanolamine (TEA) and co-monomer 
N-vinylpyrrolidone (NVP) are required for efficient cross-linking. This technique achieved 
early success in animal and non-human primate models.36 Unfortunately, acrylate-based 
chain-growth polymerization is not ideal for encapsulating radical-sensitive islet cells, due 
in large part to the potential cytotoxicity of co-initiator (i.e., TEA),37, 38 and the formation of 
a heterogeneous network containing hydrophobic polyacrylate kinetic chains.39 It was 
reported that this reaction created a dense PEGDA hydrogel layer immediately adjacent to 
the cell surface.32 Since the coating was formed with a gradient of cross-linking densities, 
the permeability of essential nutrients, oxygen, and insulin across the gel membrane may be 
adversely affected.40 In this communication, we present a visible light-mediated thiol-
norbornene interfacial photopolymerization for forming conformal coating on islet surface. 
This visible light based step-growth gelation scheme was reported previously for forming 
bulk or micro-scale hydrogels without using co-monomer (e.g., NVP) and amine-based co-
initiator (e.g., TEA).41-43 Mechanistically, thiol-containing molecules (e.g., DTT) serve not 
only as a cross-linker, but also a co-initiator. Upon visible light exposure, thiol-containing 
molecules are deprotonated by the excited eosin-Y, thus forming thiyl radicals that are 
reactive with the norbornene moieties on PEG-norbornene (PEGNB, Fig. 1a, 2a). Unlike a 
chain-growth network that contains heterogeneous cross-links, the step-growth thiol-
norbornene photo-click reaction produces orthogonal cross-links with enhanced 
cytocompatibility (Fig. 2a).41, 44, 45
We first evaluated the cytocompatibility of cell surface initiated thiol-norbornene photo-
click reaction using MIN6 β-cell aggregates as a cell model. Cell aggregates were generated 
from culturing cells on a rotating platform shaker. To evaluate the effect of radical-mediated 
photopolymerizations while excluding the influence of a cross-linked polymer network on 
cell viability, we used only linear macromer components that permit reactions but not 
gelation (Fig. 1a), PEG-mono-methacrylate (PEGMA) in chain-growth reaction and PEG-di-
norbornene (PEGdNB) for step-growth reaction. After visible light exposure, significantly 
more dead cells were found on the surface of MIN6 cell aggregates in the chain-growth 
group where reaction was initiated by eosin-Y and TEA. At the same macromer reactive 
group concentration, chain-growth reaction was less cytocompatible compared with step-
growth photo-click reaction initiated by eosin-Y and dithiothreitol (DTT).
Next, we prepared interfacial thiol-norbornene hydrogel coating on MIN6 β-cell aggregates. 
Eosin-Y stained cell aggregates were incubated in a precursor solution containing gelling 
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components, including 8-arm PEG-norbornene (PEG8NB) and crosslinker DTT (Fig. S1a & 
2a), and were exposed to bright visible light (30 mW/cm2 at 555 nm). In these experiments, 
aggregate density was fixed at approximately 500 aggregates/mL and more than 200 
aggregates were analysed. Representative phase contrast images revealed the formation of a 
thin thiol-norbornene hydrogel coating on the surface of cell aggregates after only 30 
seconds of light exposure (Fig. 2b, left). Furthermore, live/dead staining results showed that 
the coated β-cell aggregates remained viable (Fig. 2c, left). However, this direct coating 
method (i.e., one-step incubation) produced a wider distribution of gel coating thickness, 
ranging from 20 μm to 60 μm (Fig. 2d), and averaged to approximately 33 μm (Fig. 2e). In 
addition, the one-step method only yielded a coating efficiency of 64 % (Fig. 2f), and there 
was a strong dependency between the coating thickness and the size of the cell aggregates 
(Fig. 2g). Here, coating efficiency is defined as the fraction of coated aggregates over the 
sum of all (coated and non-coated) aggregates. While one-step coating method is easy and 
cytocompatible to β-cell aggregates, it did not show high coating efficiency and consistency. 
Thus, it is imperative to establish a coating strategy that provides high consistency and 
repeatability for isolated islets, which are heterogeneous in size (a few tens to a few 
hundreds micron).46
We hypothesized that the conformal coating results could be improved by providing 
additional thiols near the surface of the cell aggregates. Our recent work has shown that 
PEG exhibits affinity to eosin-Y.47 Hence, we reasoned that incubating eosin-Y stained 
aggregates with PEG-di-thiol (PEGdSH) would allow PEGdSH to anchor on the surface of 
cell aggregates via affinity binding to eosin-Y that was pre-absorbed on the aggregate 
surface (Fig. S1b). To perform this experiment, stained aggregates were incubated in 
PEGdSH before suspending in macromer solution containing PEG8NB with DTT (Fig. 
S1b). After 30 seconds of light exposure, similar conformal hydrogel coating formed on β-
cell aggregates (Fig. 2b, right). This two-step coating process was also cytocompatible to 
MIN6 aggregates (Fig. 2c, right). Although slightly more cell death was observed on the 
aggregate surface (potentially due to increased thiyl radical concentration near the surface of 
aggregates, Fig. 2c, right), the two-step incubation process produced thiol-norbornene 
conformal gel layer with a narrower distribution of coating thickness (Fig. 2d, ~20 to 40 μm) 
and a lower average coating thickness (Fig. 2e, 26 μm). More importantly, the two-step 
coating method yielded higher coating efficiency (Fig. 2f, 80 %) and a reduced dependency 
between coating thickness and the size of cell aggregates (Fig. 2g). Future work will focus 
on fine tuning the two-step coating procedure, in particular PEGdSH incubation time and 
concentration, to improve the viability of aggregates while maintaining the high coating 
efficiency.
Results shown in Fig. 2 have revealed the benefits and importance of additional PEGdSH 
incubation in interfacial thiol-norbornene photopolymerization. Therefore, we further 
investigated the effect of PEGdSH on coating thickness and efficiency. In general, the thiol-
norbornene coating thickness decreased with increasing molecular weight (MW) of 
PEGdSH (i.e., from 35 μm, 26 μm, to 13 μm for 2 kDa, 3.4 kDa, and 10 kDa PEGdSH, 
respectively, Fig. 3a-d & S2a). The use of higher MW of PEGdSH resulted in decreased 
coating efficiency (Fig. S2b, from 98 % to 64 %). It is worth mentioning that in these 
experiments, the concentration of PEGdSH was maintained at 20 wt%. PEGdSH at a lower 
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MW has higher thiol content when comparing with its counterpart at a higher MW and at the 
same macromer concentration. Therefore, increased coating thickness and efficiency at a 
lower PEGdSH MW were likely a result of increased availability of thiols near the surface 
of the aggregates, which accelerated the thiol-norbornene cross-linking reaction.
When the polymerization time was increased from 20 to 60 seconds, gel thickness also 
increased (from 15 to 43 μm, Fig. 3e & S3a). Longer polymerization time resulted in higher 
coating efficiency (from 53 % to 98 %, Fig. S3b) but also increased the likelihood of 
encapsulating more than one aggregate per gel capsule (~20 % at 60 seconds). The later 
would increase the volume of the islet transplants and might not be ideal for minimally 
invasive surgery. A large graft volume also increases diffusion path, which could reduce the 
responsiveness of the encapsulated islets to glucose. When the concentration of PEG8NB in 
the precursor solution was increased from 10 wt% to 20 wt%, gel thickness increased from 
14 to 26 μm (Fig. 3f & S4a). The use of a higher PEG8NB concentration also increased 
coating efficiency (from 24 % to 84 %, Fig. S4b). Using bulk thiol-norbornene hydrogels, 
we showed that the mesh size of these step-growth hydrogels depends on the concentration 
of PEG8NB. Based on the known average molecular weight between crosslinks and the 
Flory-Rehner theory of elasticity, the mesh size of a step-growth hydrogel with an ideal 
network (e.g., PEG8NB-DTT hydrogel) should be 9.1 nm (Equation S1 to S6).48 The mesh 
sizes of all thiol-norbornene hydrogels prepared here (Fig. S5a, from 15.1 nm to 9.9 nm for 
5 to 20 wt% of PEG8NB, respectively) were all much larger than the hydrodynamic radius 
of insulin (Fig. S5a, RH,ins = 2.0 nm).49 Furthermore, we estimated that the diffusion 
coefficients of insulin (Dg) are between 1260 to 980 μm2/sec (Fig. S5b) in thiol-norbornene 
hydrogels prepared from 5 to 20 wt% of PEG8NB. The diffusivities of insulin in the swollen 
hydrogel were slightly lower than that in aqueous buffer solution (D0: ~1500 μm2/sec).50 
These estimations suggest that the diffusion of insulin from the highly swollen thiol-
norbornene hydrogels will be affected only minimally.
Following the optimization of interfacial thiol-norbornene photopolymerization conditions 
using MIN6 cell aggregates, we prepared orthogonal thiol-norbornene hydrogel conformal 
coating on isolated mouse islets. Here, a non-degradable macromer PEGaNB was used to 
coat islets for long-term culture. It is worth mentioning that thiol-norbornene hydrogels 
formed from PEGa8NB have similar degree of cross-linking efficiency (i.e., gel fraction 
above 90 %) and swelling (up to 2 weeks) when compared with hydrolytically labile ester-
containing PEG8NB (Fig. S6). While hydrogels formed from hydrolytically labile PEG8NB 
showed significant degradation after three weeks in PBS, no gel degradation was observed 
in gels formed from hydrolytically stable PEGa8NB (Fig. S6c). As shown in Fig. 4a, islets 
coated via visible light-mediated interfacial thiol-norbornene photopolymerization remained 
viable. Furthermore, the hydrogel layer maintained its stability throughout 2 weeks of in 
vitro culture (Fig. 4b, 4c & 4d). The average thickness of the conformal coating was about 
37 μm with 90 % of coating efficiency (data not shown). In long-term in vitro culture of 
primary islets (14 days), we observed the darkening of islets core. This phenomenon was 
common in islet culture as previously reported by Dionne et al. The authors attributed the 
result to necrosis at the islet core.51 As can be seen in Fig. 4c (top), the cellular debris was 
found free floating in culture media with the non-coated islets. On the other hand, the dark 
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debris was ‘trapped’ within the conformal coating layer on the coated islets. These results 
suggest that the coating could serve as a bi-directional barrier for blocking the infiltration of 
host immune cells, and for preventing the liberation of graft debris to the transplantation site 
that would otherwise trigger host immune response.52, 53 Future work will focus on 
addressing the inflammatory response of coated islets in vivo using mouse models.
To examine insulin secretion from the coated islets, static glucose-stimulated insulin 
secretion (GSIS) was performed at day 2 and day 14 (Fig. 4e & 4f). Within each non-coated 
or coated islets group, statistically significance (p < 0.05) was found between insulin 
secretion at 2.5 mM and 25 mM glucose. Based on the results of GSIS index, which is the 
ratio of insulin secretion in high glucose buffer to low glucose buffer, we found no statistical 
significance between thiol-norbornene hydrogel coated and non-coated islets throughout 2 
weeks of in vitro culture (Fig. S7). The results of static GSIS test suggest that the islets 
remained viable and functional after thiol-norbornene conformal gel coating. In Fig. 4d and 
4e, the amounts of insulin secretion by the coated islets are significantly higher than the non-
coated islets (Fig. 4d and 4e). This might be the stress induced by gel coating on the surface 
of islets (Fig. 4a, bottom). While static GSIS results here have revealed that the thiol-
norbornene gel coated islets remained viable and functional, future experiments will include 
glucose perfusion GSIS study to ensure that the hydrogel coating does not negatively affect 
insulin release dynamics.
Conclusions
In summary, we have developed a visible light-mediated thiol-norbornene interfacial coating 
process to prepare step-growth conformal hydrogel coating on islet surface. Using MIN6 β-
cell aggregates as a model, we evaluated the parameters critical in determining coating 
thickness (e.g., MW of PEGdSH, polymerization time, and macromer concentration). The 
results of live/dead staining and GSIS demonstrated high cytocompatibility of thiol-
norbornene hydrogel coating on murine islets. This visible light mediated thiol-norbornene 
interfacial photopolymerization provides an alternate coating option and should be of great 
interest to the field of islet transplantation. Future work will focus on modifying thiol-
norbornene gel formulation to create multi-functional immuno-isolation barrier, and on 
determining the inflammatory response and long-term efficacy of the transplanted coated 
islets on maintaining euglycemia.
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(a) Schematic of visible light-mediated interfacial chain-growth (top) or step-growth thiol-
norbornene (bottom) photopolymerization (EY: eosin-Y). (b) Viability of MIN6 cell 
aggregates after non-gelling interfacial photopolymerization reactions (Green: live cells. 
Red: dead cells. Scales: 100 μm).
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(a) Schematic of visible light-mediated step-growth orthogonal thiol-norbornene reaction to 
form idealized hydrogel network. (b) Representative phase-contrast images of the conformal 
coated aggregates. (c) Representative live/dead stained images of the conformal coated 
aggregates (Scales: 50μm). (d-f) Effects of coating methods on (d) the cumulative 
distribution of conformal gel coating thickness, (e) the average coating thickness, and (f) the 
percent of coated aggregates. (g) Effect of aggregate diameter on thiol-norbornene 
conformal coating thickness. (One-step: 20 wt% PEG8NB-DTT and 30 seconds of light 
exposure. Two-step: 20 wt% PEG8NB-DTT, 3.4 kDa PEGdSH and 30 seconds of light 
exposure. Mean ± SEM, n > 200 aggregates)
Shih et al. Page 9










(a-c) Representative phase-contrast images of MIN6 cell aggregates with thiol-norbornene 
conformal gel coating (two-step coating method). PEGdSH MW: (a) 2 kDa, (b) 3.4 kDa, and 
(c) 10 kDa. Arrows and dashed lines indicate the boundary of the hydrogel coating (Scales: 
50 μm). (d-f) Parameters affecting thiol-norbornene conformal coating thickness: (d) 
molecular weight of PEGdSH, (e) photopolymerization time, and (f) concentration of 
macromer PEG8NB. Coating conditions: (a-d) 20 wt% of PEG8NB-DTT and 30 seconds of 
light exposure. (e) 20 wt% of PEG8NB-DTT and 3.4 kDa of PEGdSH. (f) 3.4 kDa of 
PEGdSH and 30 seconds of light exposure (Mean ± SEM, n > 200 aggregates).
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(a) Representative live/dead stained images of non-coated and coated CD1 mice islets (24 
hours after coating). (b-c) Representative phase contrast images of non-coated (top) and 
coated (bottom) CD1 mice islets on day 2 (b), and day 14 (c). Arrows and dashed lines in (b-
c) indicate the boundary of the hydrogel coating (Scales: 50 μm). (d-e) In vitro glucose 
stimulated insulin secretion (GSIS) of isolated islets on (d) day 2 and (e) day 14. Asterisks 
(*) and percent signs (%) indicate statistical significance between 2.5 and 25 mM of glucose 
within each group, and between non-coated and coated islets within each glucose 
concentration (Mean ± SEM, p < 0.05), respectively. Coating conditions: 3.4 kDa PEGdSH, 
20 wt% PEGa8NB-DTT, 25 seconds light exposure.
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